BioSpace News Archive

Life Biosciences, a pioneering life sciences company targeting the biology of aging, today announced the publication of preclinical research demonstrating clinical benefit of its chaperone-mediated autophagy activator platform in mice models of Alzheimer’s disease.

We are pleased to announce that MediPines AGM100™, a non-invasive pulmonary gas exchange analyzer, was selected as a finalist in the 2021 Medical Design Excellence Awards.

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its first quarter 2021 financial results before the market opens on Thursday, May 6, 2021.

Rockwell Medical, Inc. (Nasdaq: RMTI), today announced that it presented data from a clinical feasibility study reviewing the practice patterns of iron deficiency anemia (IDA) in home parenteral nutrition patients at the National Home Infusion Association’s (NHIA) 2021 Annual Conference

DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, April 29, 2021 , at 5:00 p.m. Eastern Time . The company plans to release its results after market close the same day.

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report first quarter 2021 financial results on Thursday, May 6, 2021 , after the U.S. financial markets close.

Versiti, Inc., one of the nation’s leading blood health and research organizations, today announced the appointment of Michael Deininger , MD, PhD, as Executive Vice President, Chief Scientific Officer and Director of the Milwaukee -based Versiti Blood Research Institute, its world-renowned blood research center.

PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK) First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to Obtain FDA Approval $20MM Milestone Payment Earned by AnaptysBio Upon FDA Approval; Additional $45MM and $165MM Milestones Due Upon Dostarlimab Regulatory and Commercial Milestones, Respectively AnaptysBio Due to Receive 8% to 25% Royalty on Global Net Sales

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release preliminary financial results for the first quarter of 2021 after the market close on Thursday, May 6, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.